Literature DB >> 10875804

Comparison of the protective efficacy of bacille calmette-Guérin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis.

A Williams1, A Davies, P D Marsh, M A Chambers, R G Hewinson.   

Abstract

The aim of this study was to compare protection by bacille Calmette-Guérin (BCG) vaccination against aerosol challenge with either Mycobacterium bovis or Mycobacterium tuberculosis in guinea pigs. Animals were challenged 5 weeks after vaccination with 10 or 100 lung lesion-forming units (lfu) of M. bovis or M. tuberculosis. Four weeks after challenge, numbers of lung lesions and counts of viable mycobacteria in spleens were high in saline-immunized animals. In contrast, BCG vaccination resulted in fewer lung lesions; after challenge with 10 and 100 lfu, the reduction was greater in animals infected with M. bovis (mean number of lesions, 1.17 and 31.2, respectively; P<.02) than in those infected with M. tuberculosis (mean number of lesions, 16.2 and 75.8, respectively). No mycobacteria were recovered from spleens of BCG-vaccinated animals after challenge with 10 lfu of M. bovis, whereas 4 of 6 animals had detectable spleen mycobacterial counts after challenge with M. tuberculosis. Collectively, the results suggest that BCG vaccination may confer greater protection against challenge with M. bovis than challenge with M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10875804     DOI: 10.1086/313878

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

1.  Mice fed lipid-encapsulated Mycobacterium bovis BCG are protected against aerosol challenge with Mycobacterium tuberculosis.

Authors:  Frank E Aldwell; Lise Brandt; Clare Fitzpatrick; Ian M Orme
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

2.  Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin.

Authors:  M A Chambers; A Williams; D Gavier-Widén; A Whelan; G Hall; P D Marsh; B R Bloom; W R Jacobs; R G Hewinson
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

3.  Vaccination of guinea pigs with DNA encoding the mycobacterial antigen MPB83 influences pulmonary pathology but not hematogenous spread following aerogenic infection with Mycobacterium bovis.

Authors:  Mark A Chambers; Ann Williams; Graham Hatch; Dolores Gavier-Widén; Graham Hall; Kris Huygen; Douglas Lowrie; Philip D Marsh; R Glyn Hewinson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

4.  Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs.

Authors:  Ann Williams; Rajko Reljic; Irene Naylor; Simon O Clark; Gustavo Falero-Diaz; Mahavir Singh; Stephen Challacombe; Philip D Marsh; Juraj Ivanyi
Journal:  Immunology       Date:  2004-03       Impact factor: 7.397

5.  Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis.

Authors:  Antonia Isabel Castillo-Rodal; Mauricio Castañón-Arreola; Rogelio Hernández-Pando; Juan José Calva; Eduardo Sada-Díaz; Yolanda López-Vidal
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

6.  Oral vaccination of guinea pigs with a Mycobacterium bovis bacillus Calmette-Guerin vaccine in a lipid matrix protects against aerosol infection with virulent M. bovis.

Authors:  Simon Clark; Martin L Cross; Allan Nadian; Julia Vipond; Pinar Court; Ann Williams; R Glyn Hewinson; Frank E Aldwell; Mark A Chambers
Journal:  Infect Immun       Date:  2008-06-02       Impact factor: 3.441

7.  Development of a murine nose-only inhalation model of influenza: comparison of disease caused by instilled and inhaled A/PR/8/34.

Authors:  Larry E Bowen; Katie Rivers; John E Trombley; J Kyle Bohannon; Shixiong X Li; Jeremy A Boydston; Maryna C Eichelberger
Journal:  Front Cell Infect Microbiol       Date:  2012-05-30       Impact factor: 5.293

8.  A second-generation anti TB vaccine is long overdue.

Authors:  Mauricio Castañón-Arreola; Yolanda López-Vidal
Journal:  Ann Clin Microbiol Antimicrob       Date:  2004-06-03       Impact factor: 3.944

9.  Assessment of Mycobacterium bovis deleted in p27-p55 virulence operon as candidate vaccine against tuberculosis in animal models.

Authors:  María V Bianco; Simon Clark; Federico C Blanco; Sergio Garbaccio; Elizabeth García; Angel A Cataldi; Ann Williams; Fabiana Bigi
Journal:  Biomed Res Int       Date:  2014-01-21       Impact factor: 3.411

10.  Non-replicating Mycobacterium tuberculosis elicits a reduced infectivity profile with corresponding modifications to the cell wall and extracellular matrix.

Authors:  Joanna Bacon; Luke J Alderwick; Jon A Allnutt; Evelina Gabasova; Robert Watson; Kim A Hatch; Simon O Clark; Rose E Jeeves; Alice Marriott; Emma Rayner; Howard Tolley; Geoff Pearson; Graham Hall; Gurdyal S Besra; Lorenz Wernisch; Ann Williams; Philip D Marsh
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.